Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY06006 in Postmenopausal Osteoporosis at High Fracture Risk
CTR20191183Phase 3Completed
- Sponsor
- Boan Biotech
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of CMAB807 in postmenopausal osteoporosis, sponsored by Boan Biotech. Started Jun 2019; status: completed.
02
Drugs
CMAB807
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on CTR20191183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191183.